Here are the 10-K annual reports from InfuSystem Holdings, Inc. (INFU) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow INFU and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INFU filings page.
InfuSystem Holdings, Inc. provides outpatient durable medical equipment services to hospitals, oncology practices, surgery centers and other alternate site providers through two platforms: Patient Services and Device Solutions. Patient Services focuses on clinic‑to‑home oncology and other therapies, while Device Solutions sells, rents and services infusion and wound-care equipment.
The Oncology Business is the lead service in Patient Services and generated about 87% of that segment’s 2025 net revenue, with roughly 43% from colorectal cancer treatments and 44% from non‑colorectal disease states. As of December 31, 2025, the rental fleet had a historical cost of $109.1 million and the company employed 473 people.
InfuSystem highlights competitive advantages from nearly 840 third‑party payer networks, a large pump fleet and seven U.S. and Canadian locations, but warns of extensive risks, including reimbursement changes, dependence on a major pump supplier, regulatory compliance, government shutdowns, cybersecurity threats, tax and macroeconomic uncertainty, and potential limits on using $5.8 million of U.S. federal net operating loss carryforwards.